evid materi us
pharmaci prove disrupt reduc barrier access
pull patient mix earlier expect
inflect look durabl guidanc look conserv
execut seamlessli multipl front
commerci pipelin margin expans pt
beat top-line number momentum surpris upsid
deliv sale vs mse beat driven strength
across us intern omnipod preview expect beat
base momentum stabil though surpris higher pt
momentum acceler us omnipod sale vs mse
driven pharmaci pay go model drive adopt
intern omnipod sale came vs due commerci
traction post-ypsom impli beat region manag rais
top-lin guidanc revenu
roughli twice beat driven primarili aforement catalyst
compani deliv gross margin vs mse gross margin
guidanc in-lin gross margin re-affirmed
expect gross margin may lower back half driven
second manufactur line come live new acton facil meanwhil
manag guid oper expens higher year y/i increas
vs previous compani reinvest sale upsid
drove us inflect record new patient start primari
reason us omnipod strength manag cite pharmaci pay
go model improv access reduc barrier adopt
exampl intens market commentari increas traction
surpris encourag given intens opportun
coverag pharmaci also improv end
quarter expect pbm headwind unchang
due shift toward pay-as-you-go suggest fewer pdm
continu off-set new patient higher-asp omnipod possibl
ad patient pharmaci quarter support two
assumpt manag comment pharmaci volum increas
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
total us instal base patient
impli increas patient midpoint
us revenu beat divid pod per patient/ quarter time asp
impli patient add year rais guidanc
total us omnipod sale comfort high end
respect model impli pt deceler
vs stabil impli upsid vs
ex-u underli growth track ahead plan mark anniversari
ypsome estim underli growth ex-ypsom gross-up
quarter versu guidanc growth
prior quarter ex-u guidanc suggest underli
growth back-half suggest pt q/q step growth
like prove conserv growth rate line impli
upsid model high end
multipl product catalyst ada receiv multipl updat
product catalyst go forward see manag re-affirmed horizon
ap pivot begin later year posit broad commerci
roll-out horizon function competit
better form factor set stage competit integr offer
pharmaci see highli differenti offer vs peer ultim
leav us encourag prospect sens may
also provid data ada mid-jun manag confirm
submit fda could see approv earli though
comment like nich product versu
timelin provid see possibl
lrp look conserv pt discuss follow ada
see visibl path increas mark
inflect growth remain confid manag abil meet
target especi given market expans natur share captur
opportun embed pay go pharmaci evidenc
quarter result model impli omnipod sale compound-annual-growth-rate
deliv sale line lrp guidanc given
inflect driver adopt pharmaci traction pay-as-you-go broader
coverag traction path emerg greater sale
continu see path margin guidanc mid-teen om
model om driven manufactur shift
acton sale shift pharmaci rais price target
prior reflect multipl ev sale rais
intermedi term estim pleas see exhibit model chang
long-term omnipod growth sustain
long-term omnipod growth sustain
price target reflect ev sale multipl
base case roughli in-lin high growth smid cap
ev/sal support dcf analysi
ev/sal support dcf analysi
post-ypsom anniversari ex us reacceler underli
growth medicar shift pharmaci acceler us growth ap
competitor prove market expans immateri omnipod growth
expand larger type market disclosur
addit drug deliveri deal materi increas valu busi
greater scale oper effici pharmaci channel drive margin
opportun next year
ev/sal support dcf analysi
ev/sal support dcf analysi
ex us growth improv meaning follow anniversari ypsome us
growth remain stabl driven medicar shift
pharmaci mdi pediatr posit insul omnipod ap
competitor risk remain path sale pipelin
product sustain growth gm clear like floor dash roll
horizon ap launch base case reflect
ev sale multipl discount high growth smid cap
ev/sal support dcf analysi
ev/sal support dcf analysi
ypsome disrupt prove difficult manag ex us ap competit slow
pediatr mdi adopt medicar expans fail off-set
competit headwind dash adopt modest ap timelin slip u-
fail expand reach type market drug deliveri
sale declin biosimilar lead neulasta declin path profit
becom less clear greater invest requir support growth
remain comfort near-term
revenu trend omnipod somewhat
de-risk competit ap launch given
mdi posit shift pharmaci
drive near term volatil
longer term driver growth path
revenu becom clear driven
channel shift pharmaci medicare/unh
ex us growth
us new anima patient sustain mid-teen
growth us
profit concern
direct distribut ex us shift
pharmaci show us path gm
medicar shift
pharmaci sustain us growth direct
path profit improv
direct distribut ex us shift
pharmaci us
dash roll provid
foundat cgm integr ap
dash roll-out on-going us ex-
risk achiev price
market share ap competitor ii limit
convers anima patient iii ex-u
fail recov follow ypsome
disrupt iv dash horizon ap
timelin slip path profit
ypsome transit ii disclosur
abil drive manufactur oper
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
y/i growth new patient add
dollar million except per share data
cash equival
prepaid expens current asset
accru expens current liabil
current portion long-term debt
current portion capit leas oblig
lt debt net discount
dollar million except per share data
non-cash interest expens
loss extinguish long-term debt
provis bad debt
net chang work capit
proce purchas short term invest
proce divestitur
net invest
princip payment capit leas oblig
proce issuanc common stock
payment withhold tax connect
vest restrict stock unit
proce issuanc long-term debt net
repay long-term debt
net financ
effect exchang rate chang cash
begin period
end period
